NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.): 2 sponsored US clinical trials, none currently recruiting.
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Onychomycosis/Onycholysis and Tinea Pedis, with 1 trials.
Mid-pack sponsor footprint
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
NCT02228850
Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis
NCT00691184
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Therapeutic Areas
How the NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) early-phase archive is shaped
2 indexed studies, none listed as recruiting (0% open); 2 completed (100%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Onychomycosis/Onycholysis and Tinea Pedis (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.): archived-pipeline peers nationwide
Peers matched on 2 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 archived trials
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) page
2 registered trials is a research-attention snapshot, not an endorsement of NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) or any single study.
- None of NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Onychomycosis/Onycholysis and Tinea Pedis is the condition NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Onychomycosis/Onycholysis and Tinea Pedis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.